الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
In the present study, non alcoholic fatty liver disease and steatohepatitis were induced by mixing animal fat tallow with standard show pellets and the use of fructose in drinking water (10%). Male WISTAR rats were exposed to high carbohydrate high fat diet for 12 and 18 weeks. The group of rats fed with HCHF diet for 12 weeks suffered from non significant elevation in liver weight index and liver IL-1β with significant increased serum levels of liver enzymes, total cholesterol, triglycerides and LDL cholesterol with elevated concentrations of liver MDA, TNF-α and IL-18 in addition to focal lytic necrosis, hepatocellular ballooning and moderate inflammatory cellular infiltration (score 2) after histopathological examinatio. The consumption of HCHF diet for 18 weeks resulted in non significant increased liver weight index and liver MDA concentration with significant elevated serum levels of liver enzymes, total cholesterol, triglycerides and increased concentrations of liver TNF-α, IL-1β and IL-18 in comparison with normal control group in addition to fatty liver (steatosis) (score 3) after histopathological examination. The group of rats treated with dapagliflozin (DAPA) showed significant improvement and reduction in serum levels of liver enzymes total cholesterol, triglycerides, LDL cholesterol and decreased concentrations of liver TNF-α in comparison with the other two groups received HCHF diet for 12 and 18 weeks and these results of DAPA group were closely similar to normal control group with no significant difference. The group of rats which administered DAPA showed significant reduced levels of liver MDA in comparison with the group of rats consumed HCHF diet for 12 weeks in contrast for HCHF 18 week group, while DAPA group decreased concentrations of liver IL-1β and IL-18 when compared to the group of rats consumed HCHF diet for 18 weeks rather than HCHF12 week group. Histopathologically, this group showed improvement and reduction of steatosis with mild inflammatory cellular infiltration (score 1). To our knowledge, this is the first study to document the potential efficacy of DAPA on fatty liver and steatohepatitis.